Early View

Research letter

mTORC1 Hyperactivation in LAM Leads to *ACE2* Upregulation in Type II Pneumocytes: Implications for COVID-19

Yan Tang, David J. Kwiatkowski, Elizabeth P. Henske

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

mTORC1 Hyperactivation in LAM Leads to *ACE2* Upregulation in Type II Pneumocytes: Implications for COVID-19

Yan Tang[1], David J. Kwiatkowski[1*], Elizabeth P. Henske[1*]

[1] Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

Corresponding Author (*):

David J. Kwiatkowski, M.D, Ph.D

Email: dk@rics.bwh.harvard.edu

Elizabeth P. Henske, M.D

Email: EHENSKE@BWH.HARVARD.EDU

20 Shattuck Street, Division of Pulmonary Medicine and Critical Care Medicine,

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

Take-Home Message:

Increased pneumocyte expression of the SARS-CoV-2 entry receptor ACE2 in Lymphangioleiomyomatosis (LAM) is associated with upregulation of interferon pathways in natural killer cells as wells as increased IL6 expression in LAM-associated fibroblasts.

To the Editor:

Respiratory failure is among the gravest outcomes of COVID-19, and most of the severe cases are associated with significant lung comorbidities[1]. Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease of women caused by mutations in tuberous sclerosis genes, resulting in aberrant hyperactivation of the mTOR complex 1 (mTORC1) signaling network in LAM cells, which are of mesenchymal origin [2]. The risk of COVID-19 in LAM is unknown.

We profiled the explant lungs of five women with LAM (46,659 cells) by single cell RNA sequencing (scRNA-seq) using 10x genomics Chromium platform. Low quality cells, defined as cells in which fewer than 200 different genes were detected or with mitochondrial gene percentage higher than 10%, were filtered out. Raw data was normalized, and log transformed as previously described[3]. Batch effects of datasets from different platforms were removed, and datasets were integrated using Seurat[4]. Major cells types identified in LAM using the algorithm SingleR [5] (Fig. 1a) included epithelial cells (type I and type II pneumocytes, ciliated cells), immune cells (T cells, B cells, macrophages, dendritic cells, natural killer cells), and endothelial cells (lymphatic endothelial cells and blood endothelial cells). The cell type annotation was further confirmed by plotting marker genes manually. Re-clustering of pneumocytes showed that *ACE2* was primarily expressed in type II pneumocytes, while *TMPRSS2* was expressed in all epithelial cell types (Fig. 1a), consistent with prior data[6-8]. The LAM lungs were compared with existing scRNA-seq datasets (GSE122960) of healthy lungs (n=8)[9], derived from donors who had died from stroke, hemorrhage, brain injury, or gunshot. One healthy control with an Asian genetic background was excluded because of reports that Asian individuals have higher expression of *ACE2* than other populations [10].

The percentage of type II pneumocytes expressing *ACE2* in LAM lungs (2.6%) was significantly higher than in healthy lungs (0.9%, p=0.03, Mann–Whitney U test, Fig. 1a).

Compared with healthy lungs, *ACE2* expression was also higher in LAM-associated type I (1.5% vs. 0.7%, p=0.14) and ciliated cells (1.1% vs. 0.5%, p=0.39). *TMPRRS2* expression was also significantly higher in LAM-associated type II pneumocytes (56% vs. 45%, p=0.048) (Fig. 1a) and ciliated cells (33% vs. 22%, p=0.14) compared to healthy lung. Significant upregulation of *ACE2* was not observed in single cell datasets from other lung conditions compared to healthy lungs, including pulmonary fibrosis (GSE122960) (n= 4) [9] and lungs with cancer (n = 2)[8] and infectious diseases (n=6)[8], with the exception of one lung from an HIV+ and Mycobacterium tuberculosis (TB)+ patient [8](Fig. 1a). These observations indicate that increased pneumocyte expression of *ACE2* and *TMPRSS2* is specific to LAM and not seen in other lung conditions, and suggest that the mTORC1-hyperactive LAM cells may induce this effect.

We further investigated whether *ACE2+/TMPRSS2+* cells in LAM are primed for infection beyond the expression of these receptors for virus entry. Gordon *et al.* identified 332 human proteins physically interacting with SARS-CoV-2 proteins in HEK293T cell expression experiments [11]. We calculated COVID module score based on the average expression of these 332 genes using Seurat[4] in LAM pneumocytes. The significant upregulation of COVID module score was seen in *ACE2+/TMPRSS2+* cells compared to *ACE2+/TMPRSS2-* cells (Mann-Whitney U-test p=5.1E-5) and *ACE2-/TMPRSS2-* cells (Mann-Whitney U-test p=1.1E-14) (Fig. 1a). Consistent with this, the percentage of cells expressing each of these 332 individual genes was highest in the *ACE2+/TMPRSS2+* cells (Mann–Whitney U test p=2.2E-16, *ACE2+/TMPRSS2+* versus *ACE2+/TMPRSS2-*) and lowest in the *ACE2-TMPRSS2-* cells (Mann–Whitney U test p=2.2E-16, *ACE2+/TMPRSS2+* versus *ACE2-/TMPRSS2-*) (date not shown due to limited space). These analyses demonstrate that *ACE2* expression in LAM correlates with increased expression of genes whose protein products interact with, and are hypothesized to enable virus replication.

To identify pathways co-regulated with the upregulation of *ACE2* in LAM, we performed pathway analysis, comparing expression of *ACE2*+ vs. *ACE2*- epithelial cells in the LAM dataset. Both hypoxia and IL-6-induced acute-phase response pathways were upregulated in the LAM *ACE2*+ pneumocytes. The master transcription factor of the IL-6 pathway, *STAT3*, was upregulated in LAM *ACE2*+ pneumocytes, along with four genes directly or indirectly regulated by *STAT3*: *FGG*, *CXCL1*, *HP*, and *HMOX1* (Fig. 1b), suggesting IL-6 might be driving these effects. Consistent with this, we found increased IL-6 in LAM-associated fibroblasts compared to mesenchymal cells derived healthy lungs (Fig. 1b), supporting the concept that IL-6 drives *ACE2* expression in LAM.

ACE2 is an interferon-stimulated gene in human airway epithelial cells [12]. We used lists of genes involved in IFN-alpha/beta signaling via JAK/STAT (type I) and interferon gamma (type II) signaling pathways (MetaCore from Clarivate Analytics) to calculate cell type-specific interferon pathway activity scores in healthy lungs compared with LAM lungs [4]. In the LAM lungs, both type I and type II interferon pathways were upregulated in natural killer (NK), but not in T cell, B cells, or macrophages (Fig. 1b). Many key regulators in the IFN pathways were significantly upregulated in LAM NK cells, including *INFG* and *INFGR1* (Fig. 1b). In addition, interferon gamma expression was upregulated in LAM-associated NK cells compared to healthy lungs (Fig. 1b). These analyses suggest that interferon secretion by LAM NK cells into the tumor microenvironment may cooperate with IL-6 to upregulate *ACE2* expression in LAM epithelial cells (Fig. 1b).

mTORC1, which is hyperactive in LAM, promotes protein synthesis and cellular growth, and is believed to be used by SARS-CoV-2 to favor replication [13]. LARP1, an mTOR-regulated translational repressor, is among the 332 virus-interacting proteins identified by Gordon *et al.* [11], and Appelberg *et al.* identified crosstalk between SARS-CoV-2 and mTOR/HIF-1 signaling [14]. Therefore, we investigated the effect of rapamycin (an allosteric mTORC1 inhibitor) on gene

expression in these pathways in primary cells, derived from a dissociated renal angiomyolipoma tumor carrying a *TSC2* mutation obtained at the time of surgery. Angiomyolipomas are benign tumors that share common genetic mutations with LAM and occur in half of women with LAM. Primary cultures were treated with 20nM rapamycin or DMSO for 24 hours and subjected to single cell profiling. To overcome the challenge of inflated zeroes in single cell data, we used MAGIC[15] to impute gene expression in each cell. Using the same pathway gene lists described above (MetaCore from Clarivate Analytics), we observed that rapamycin treatment had major effects in downregulating both type I and type II interferon pathways (Mann-Whitney U-test $p < 2.2E-16$ for all comparisons) (Fig. 1c), including many interferon stimulated genes (e.g. IFIT, Interferon Induced Protein With Tetratricopeptide Repeats family) (Mann–Whitney U test $p < 0.001$ for all genes) (Fig. 1d). IL-6-induced acute-phase response genes that were enriched in *ACE2*+ cells were also downregulated by rapamycin treatment (Mann-Whitney U-test $p < 0.001$) (Fig. 1d). The expression of the 332 SARS-CoV-2-interacting host proteins also showed downregulation by rapamycin treatment in general (data not shown due to limited space). These analyses suggest that mTORC1 inhibition may have benefit in SARS-CoV-2 by decreasing the IFN and IL6 pathways that promote the expression of ACE2.

In conclusion, we observed an increased percentage of type II pneumocytes expressing *ACE2* in LAM lungs, associated with upregulation of the Type I and Type II interferon pathways in LAM-associated NK cells, and increased *IL6* expression in LAM-associated fibroblasts, suggesting that both mechanisms drive increased *ACE2* expression. Similar mTORC1-dependent mechanisms may contribute to *ACE2* expression in other settings. An advantage of using LAM as a model system is the consistent activation of mTORC1 within LAM cells. While other tumors often have elevated mTORC1 activity, it is rarely present as a single, defining genetic feature, making it much more difficult to pinpoint these types of non-cell autonomous mechanisms. How mTORC1 signaling within tumor cells impacts *ACE2* expression in

neighboring epithelial cells will require additional single-cell datasets using genetically defined specimens, and/or mouse models in which mTORC1 is specifically perturbed. Alterations in mTORC1 signaling may also be present in non-malignant disorders such as IPF. We analyzed a published single cell dataset of four IPF samples, and did not find a significant increase in *ACE2* expression in type II pneumocytes compared to healthy donors.

Notably, using cultured primary cells from a LAM-related tumor, angiomyolipoma, we discovered that rapamycin treatment downregulated the interferon pathways and also downregulated a set of previously identified putative SARS-CoV2-interacting proteins. From a clinical perspective, the upregulation of *ACE2/TMPRSS* expression in LAM lung epithelial cells suggests that women with LAM may be at increased risk of severe COVID-19 infection. Although all of the LAM specimens studied here are from lung transplantation tissue representing advanced disease, since our analyses link mTORC1 activity to the expression of ACE2 and TMPRSS2, we speculate that this would also be true in mild disease. Future studies will be needed to confirm this. The downregulation of IL-6 and interferon signaling in response to rapamycin suggests that rapamycin treatment may have benefit both in limiting initial infection upon virus exposure and progression of COVID-19 to pneumonia both in general and in women with LAM. This is particularly important for patients already taking rapamycin for LAM or other diseases. Further analyses including clinical trials will be necessary to assess the potential benefit of rapamycin for both aspects of COVID-19.

Acknowledgments

Author Contributions

Y.T., D.J.K, E.P.H: designed the study. Y. T: performed all experiments, analyzed data, interpreted the data and wrote the manuscript. D.J.K and E.P.H: reviewed and evaluated the data and revised the manuscript. All authors read and approved the manuscript.

Competing Interests statement

There is no conflict of interest to report and the authors declare no competing financial interests.

Figure Legend

Fig. 1| Expression of *ACE2* and *TMPRSS2* by epithelial cells is upregulated in LAM lungs, which is linked with upregulation of interferon pathways and interferon gamma expression in natural killer cells as wells as increased *IL6* expression in LAM-associated fibroblasts.

a. Increased expression of *ACE2* and *TMPRSS2* in LAM. UMAP plot shows major cell types identified in five LAM lung specimens. Re-clustering of pneumocytes showed that *ACE2* was expressed primarily in type II pneumocytes, while *TMPRSS2* was expressed by all subtypes. Scale bar color intensity represents normalized expression. Significantly higher percentage of type II pneumocytes expressed *ACE2* and *TMPRSS2* in LAM lungs compared to healthy human lungs (Mann–Whitney U test). Violin plot showing highest COVID score in *ACE2+/TMPRSS2+* cells.

b. Interferon secretion by LAM NK cells may cooperate with IL-6 to upregulate *ACE2* expression in LAM epithelial cells. In the IL-6-induced acute-phase response pathway, master transcription factor STAT3 and four downstream genes were significantly upregulated in *ACE2+* epithelial cells. LAM-associated fibroblasts showed upregulation of *IL6* expression compared to fibroblasts derived from healthy lungs. Interferon pathways, as well as key genes (*IFNG* and *IFNGR1*), were upregulated in NK cells in LAM. Interferon gamma expression is significantly upregulated in LAM-associated NK cells compared to that of healthy lungs. Dot size represents fraction of cells within that type expressing interferon gamma (*IFNG*). Dot color intensity represents average expression within that cell type.

c. Rapamycin treatment downregulated interferon pathways. Violin plot shows that both type I (IFN-alpha/beta signaling via JAK/STAT) and type II (antimicrobial actions of IFN-

gamma pathway) interferon pathways were downregulated by rapamycin treatment of a primary culture of a TSC2-mutant angiomyolipoma.

d. Rapamycin treatment downregulated interferon-induced genes in a primary culture of a TSC2-mutant angiomyolipoma. UMAP of cells in control group (red) and cells in rapamycin treatment group (cyan). Scale bar color intensity represents imputed expressions.

Reference

1. Wang, D*., et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* (2020).
2. Henske, E.P. & McCormack, F.X. Lymphangioleiomyomatosis - a wolf in sheep's clothing. *J Clin Invest* **122**, 3807-3816 (2012).
3. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* **36**, 411-420 (2018).
4. Stuart, T*., et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902 e1821 (2019).
5. Aran, D*., et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol* **20**, 163-172 (2019).
6. Sungnak, W*., et al.* SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nature Medicine* **26**, 681-687 (2020).
7. Qi, F., Qian, S., Zhang, S. & Zhang, Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Commun* **526**, 135-140 (2020).
8. Ziegler, C.G.K*., et al.* SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* **181**, 1016-1035.e1019 (2020).
9. Reyfman, P.A*., et al.* Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. *Am J Respir Crit Care Med* **199**, 1517-1536 (2019).
10. Cao, Y*., et al.* Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov* **6**, 11 (2020).
11. Gordon, D.E*., et al.* A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* (2020).
12. Ziegler, C.G.K*., et al.* SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* (2020).
13. Kuss-Duerkop, S.K*., et al.* Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. *PLoS Pathog* **13**, e1006635 (2017).
14. Appelberg, S*., et al.* Dysregulation in mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. *bioRxiv*, 2020.2004.2030.070383 (2020).
15. van Dijk, D*., et al.* Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. *Cell* **174**, 716-729 e727 (2018).

a

scRNA–seq of Five LAM Lungs

Re-clustering of pneumocytes

Ciliated
Type I
Type II

ACE2

TMPRSS2

COVID Score

Endothelial
Ciliated Epithelia
Myeloid
T cell
NK cell
B cell
Type I Epithelia
Type II Epithelia
LAM cells
Mesenchymal

ACE2+/TMPRSS2+
ACE2+/TMPRSS2–
ACE2–/TMPRSS2–

ACE2

p<0.05

LAM   Healthy   IPF   Cancer or TB+   HIV+TB+

TMPRSS2

p<0.05

LAM   Healthy   IPF   Cancer or TB+   HIV+TB+

b

NK cells

Antimicrobial actions of IFN–gamma

IFN–alpha/beta signaling via JAK/STAT

Ctrl   LAM

IFNG

Ctrl   LAM

IFNGR1

Ctrl   LAM

LAM
Ctrl

B_cell   DC   Endothelial_cell   Epithelial_cell   Macrophage   Mesenchymal_cell   Monocyte   Neutrophil   NK_cell   T_cell

Percent Expressed   0   5   10   15

Average Expression   0   1   2   3

LAM cell → Natural Killer cell
↑ mTOR   ISGs
↑ IL-6   Interferons
LAM-associated fibroblast   ↑ ACE2
↓ IL-6   Epithelial cell
         IL-6 signaling pathway

IL6

Ctrl   LAM

IL-6-induced acute-phase response pathway enriched in *ACE2*+ cells

STAT3   FGG   CXCL1   HP   HMOX1

ACE2+ ACE2–   ACE2+ ACE2–   ACE2+ ACE2–   ACE2+ ACE2–   ACE2+ ACE2–

c

Antimicrobial actions of IFN–gamma

Ctrl   Rapa

IFN–alpha/beta signaling via JAK/STAT

Ctrl   Rapa

d

Ctrl
Rapa

IFIT1

IFIT2

STAT3